Cardiac Resynchronization Therapy Market To Reach $8.21 Billion By 2033

Cardiac Resynchronization Therapy Market Growth & Trends

The global cardiac resynchronization therapy market size is expected to reach USD 8.21 billion by 2033, registering a CAGR of 6.3% from 2025 to 2033, according to a new report by Grand View Research, Inc. The key factors driving the market growth include growing initiatives by key companies, rising product advancements, and increasing product adoption by end users

The CRT market was significantly impacted by the COVID-19 pandemic. Some of the major impacts of COVID-19 on the market include demand slowdown, fall in sales, and supply chain disruption due to the cancellation of operational hurdles and elective procedures. For instance, Abbott, one of the major players in the cardiac rhythm management device business, reported a decline in revenue growth of the cardiovascular business in 2020. Boston Scientific has reported a decline in sales across all regions in 2020. By Q3 2021, the company’s sales recovered gradually with the cardiac rhythm management segment accounting for USD 1.5 billion in total revenue.

Furthermore, COVID-19 had a negative impact on Medtronic's fourth-quarter financial performance, which ended on April 24, 2020. Postponed elective and semi-elective treatments using Medtronic devices had an impact on the corporation. People's reluctance to undertake non-COVID-19 emergency procedures has an impact on the company's emerging product lines. By 2021, the company's sales had returned to positive territory. Its cardiac & rhythm management portfolio revenues increased by 11% year on year for the six months ending in October 2021.

Increasing product advancements and initiatives by key market players are expected to propel market growth in the coming years. For instance, in February 2020, Medtronic received the CE mark clearance for its cardiac resynchronization therapy defibrillators (CRT-Ds) combined with smart features such as AdaptivCRT and EffectivCRT algorithms. Similarly, in July 2020, Abbott received approval from the US FDA for its cardiac resynchronization therapy defibrillator (CRT-D) devices equipped with Bluetooth features.  

 Request a free sample copy or view report summary: Cardiac Resynchronization Therapy Market Report

Cardiac Resynchronization Therapy Market Report Highlights

• By product, the CRT-defibrillator segment accounted for the largest revenue share of 55.04% in 2024. The CRT-pacemaker segment is expected to grow at the fastest CAGR over the forecast period.

• By end-use, the hospitals segment accounted for the largest revenue share of 49.20% in 2024. The cardiac centers segment is expected to grow at the fastest CAGR over the forecast period.

• North America cardiac resynchronization therapy (CRT) market dominated with a share of 52.72% in 2024. The U.S. cardiac resynchronization therapy (CRT) market accounted for the largest market share in North America in 2024.

• North America Cardiac Resynchronization Therapy market dominated the global industry with the largest revenue share of 36.83% in 2024.

• The Asia-Pacific region has witnessed a growing demand for Cardiac Resynchronization Therapy (CRT) devices, driven by the rising prevalence of cardiovascular diseases and heart failure across countries such as China, India, Japan, and South Korea.

Cardiac Resynchronization Therapy Market Segmentation

Grand View Research has segmented global cardiac resynchronization therapy market report based on product, end-use and region:

Cardiac Resynchronization Therapy Product Outlook (Revenue in USD Million; Unit Volume in ‘000 Units; Average Selling Price [USD per Unit], 2021 - 2033)

• CRT-Defibrillator

• CRT-Pacemaker

Cardiac Resynchronization Therapy End-use Outlook (Revenue, USD Million, 2021 - 2033)

• Hospitals

• Cardiac Centers

• Others

Cardiac Resynchronization Therapy Regional Outlook (Revenue in USD Million; Unit Volume in ‘000 Units; Average Selling Price [USD per Unit], 2021 - 2033)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • South Korea

  • Australia

• Thailand

  • Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players of Cardiac Resynchronization Therapy Market

• Abbott

• Biotronik

• Medtronic

• Boston Scientific Corporation

• MicroPort Scientific Corporation

• OSYPKA MEDICAL

• MEDICO S.R.L.

• Schiller